Royalty Pharma (RPRX) Short term Debt (2019 - 2026)

Royalty Pharma has disclosed Short term Debt across 7 years of filings, most recently posting $380.0 million for Q2 2026.

• In Q2 2026, Short term Debt fell 61.98% year-over-year to $380.0 million; the TTM figure through Jun 2026 stood at $380.0 million (down 61.98% YoY), while the FY2025 annual figure was $380.0 million, down 61.92% from the prior year.
• Short term Debt came in at $380.0 million for Q2 2026 at Royalty Pharma, roughly flat from $380.0 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $999.4 million in Q2 2025 to a low of $380.0 million in Q3 2025.
• Average Short term Debt over 5 years is $792.1 million, with a median of $997.2 million recorded in 2022.
• Year-over-year, Short term Debt sank 61.88% in 2025 and plunged 61.98% in 2026.
• Over 5 years, Short term Debt stood at $997.5 million in 2022, then rose by 0.19% to $999.4 million in 2023, then dropped by 0.16% to $997.8 million in 2024, then tumbled by 61.92% to $380.0 million in 2025, then changed by 0.0% to $380.0 million in 2026.
• Per Business Quant data, the three most recent Short term Debt figures were $380.0 million in Q2 2026, $380.0 million in Q1 2026, and $380.0 million in Q4 2025.